On June 29, Hinge Health rose 5.53% in regular trading, trading at $83.335/share with turnover of $130 million, extending its strong performance throughout June.

On the news front, the company recently raised its full-year revenue guidance at the Movement 2026 investor conference to $818 million to $824 million, with the midpoint lifted by $20 million from prior guidance, significantly exceeding the FactSet consensus estimate of $801.6 million. The company also increased its Q2 revenue outlook to $200 million to $202 million versus analyst expectations of $193.8 million. Additionally, Hinge Health announced the integration of orthopedic surgery into its HingeSelect platform, creating a comprehensive musculoskeletal care offering spanning physical therapy, specialist evaluation, imaging, pre-habilitation, surgery, and post-operative recovery.

RBC Capital Markets raised its price target on the stock to $75 from $65, maintaining an Outperform rating, citing the company's long runway for growth driven by new products, expanding market opportunities, and a target operating model calling for 20%-25% revenue growth with operating margins above 35%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)